Xtandi® (enzalutamide) – Expanded indication
November 17, 2023 - Astellas and Pfizer announced the FDA approval of Xtandi (enzalutamide), for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).
Top